VKTX
Viking Therapeutics, Inc.
Stock
$29.94−0.57 (−1.87%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $502M | $706M | $903M | $362M | $155M | $202M | $248M | $276M | $302M | $21M | $13M | $14M | $756K |
| Current assets | $518M | $716M | $907M | $367M | $167M | $211M | $256M | $284M | $302M | $22M | $14M | $15M | $774K |
| Total assets | $522M | $716M | $908M | $368M | $169M | $211M | $257M | $284M | $302M | $22M | $15M | $15M | $3.0M |
| Current liabilities | $110M | $77M | $27M | $19M | $22M | $8.8M | $12M | $6.8M | $4.6M | $8.7M | $6.5M | $2.0M | $23M |
| Total liabilities | $114M | $77M | $28M | $20M | $23M | $8.8M | $12M | $7.1M | $4.6M | $8.7M | $6.5M | $6.7M | $25M |
| Shareholders' equity | $408M | $639M | $880M | $348M | $145M | $202M | $244M | $277M | $298M | $13M | $8.0M | $8.7M | −$22M |
| Shares outstanding | 116.7M | 115.6M | 112.2M | 100.5M | 78.4M | 78.4M | 74.1M | 72.6M | 72.0M | 50.9M | 23.8M | 9.7M | — |
| Current ratio | 4.72 | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 | 21.12 | 41.83 | 66.40 | 2.52 | 2.16 | 7.69 | 0.03 |